Ceftazidime-Decorated Gold Nanoparticles: a Promising Strategy against Clinical Ceftazidime-Avibactam-Resistant <i>Enterobacteriaceae</i> with Different Resistance Mechanisms-Reference-Cited by-同舟云学术

Ceftazidime-Decorated Gold Nanoparticles: a Promising Strategy against Clinical Ceftazidime-Avibactam-Resistant Enterobacteriaceae with Different Resistance Mechanisms

Published:2023-07-18 Issue:7 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Huang Zeyu¹,Liu Haifeng¹,Zhang Xiaotuan¹,Tang Miran¹,Lin Yuzhan¹,Feng Luozhu²,Ye Jianzhong¹,Zhou Tieli¹^ORCID,Chen Lijiang¹

Affiliation:

1. Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

2. School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China

Abstract

Nanoparticle-based antibiotic delivery systems are essential in combating antibiotic-resistant bacterial infections arising from acquired resistance and/or biofilm formation. Here, we report that the ceftazidime-decorated gold nanoparticles (CAZ_Au NPs) can effectively kill clinical ceftazidime-avibactam-resistant Enterobacteriaceae with various resistance mechanisms.

Funder

Key Laboratory Diagnosis and Translational Research of Zhejiang Province

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00262-23

Reference58 articles.

1. Evolution of Bacterial Persistence to Antibiotics during a 50,000-Generation Experiment in an Antibiotic-Free Environment

2. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

3. A case–control study of infections caused by Klebsiella pneumoniae producing New Delhi metallo-beta-lactamase-1: Predictors and outcomes

4. Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000–2017

5. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections